source
- Merck ends Phase 2 trial of Alzheimer’s drug MK-1167 from partner NeuphoriaMerck announced it has terminated a mid-stage Phase 2 study of an experimental Alzheimer’s therapy. The drug, called MK-1167, is an oral candidate that was being developed in collaboration with bi…
- FDA warns Genzyme's Irish site over quality questionsAn FDA warning letter sent late last month to Genzyme's Ireland-based manufacturing site, now owned by Sanofi, raises significant quality- and data-related issues. On data integrity, the warning le…Endpoints · 1mo ago↗ source
- WuXi AppTec seeks injunction over China military list